“Targeting PTP1B to treat schizophrenia”
Schizophrenia is a debilitating mental disorder that affects young adults and that can lead to cognitive decline in later years. It is characterized by social isolation and a number of symptoms including auditory hallucinations, false beliefs, and often anxiety and depression. It has been proposed that infection in early development combined with genetic risk may lead to developing schizophrenia later in life. There is also growing evidence from clinical and animal studies that metabolic defects may exacerbate or even underlie defects in neural circuits in patients with schizophrenia.